See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Trispecific antibody CS-2009 has in vivo activity

Nov. 13, 2024
Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.
BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Antibody Immuno-oncology